Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
•
Hepatology
When treating fatty liver disease with resmetirom, how often should a FibroScan be repeated to assess treatment response?
Related Questions
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
Can fatty liver disease present with elevations in alkaline phosphatase without other liver enzyme elevations (AST and ALT)?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
Do you tend to avoid the use of oral weight loss stimulant medications such as phentermine in obese patients on SSRI or ADHD treatments?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
How do you decide between bariatric surgery and a GLP-1 receptor agonist for patients with metabolic dysfunction-associated steatotic liver disease who have not met weight loss goals after six months of lifestyle interventions?
In patients with severe obesity, do you recommend a trial of GLP 1 R agonist therapy prior to bariatric surgery?
What work up do you recommend in post bariatric surgery patients who are slowly gaining back the weight despite no changes in diet?
